Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Assessing trial representativeness using serious adverse events: an observational analysis using aggregate and individual-level data from clinical trials and routine healthcare data

Fig. 3

This figure shows the ratio of observed/expected serious adverse event rates in aggregate data trials. Four selected index conditions with the largest number of eligible trials are displayed here, with the remaining conditions displayed in the supplementary appendix. The point-estimate and 95% confidence interval for the ratio for each trial is shown by the coloured points and bars, respectively. Different drug classes are separated by colour (full key displayed in supplementary appendix). The pooled ratio and 95% confidence intervals meta-analysed across all trials within each index condition is shown by the black point and line at the bottom of each plot. Findings are based on analysis of aggregate trial data from ClinicalTrials.gov (index condition, trial drug, age, sex, SAEs and follow-up) for the observed rate and individual patient data from SAIL was used to calculate the expected rate

Back to article page